Optimizing the absorption of valspodar, a p-glycoprotein modulator, part ii: quantifying its pharmacokinetic variability and refining the unavailability estimate

Journal of Clinical Pharmacology

Volumn 37, Issue 11, 1997, Pages 1009-1014

  Kovarik, J M ^a   Mueller, E A ^a   Richard, F ^b   Tetzloff, W ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Iphar Institute for Clinical Pharmacology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; UNCLASSIFIED DRUG; VALSPODAR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIDRUG RESISTANCE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; QUANTITATIVE ASSAY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CYCLOSPORINS; DOUBLE-BLIND METHOD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; MALE; P-GLYCOPROTEIN;

EID: 0030732718     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04281.x     Document Type: Article

References (13)

1. Mueller EA, Kovarik JM, Üresin Y, Fluckiger SS, Hensel S, Lücker PW, Holt B: Optimizing the oral absorption of valspodar, a P-glycoprotein modulator. I: Selecting an oral formulation and exploring its clinical pharmacokinetics/dynamics. XXX.
2. ' 2. Boote DJ; Dennis IF, -Twentymann PR, Osbourne RJ, Laburte C, Hensel S, et al: A phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance. J Clin Oncol 1996;14:610-618.
3. Sonneveld P, Marie J-P, Huisman C, Vekhoff A, Schoester M, Faussât AM, et al: Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia 1996:10:1741-1750.
4. Wijnand HP: Determination of the absolute bioavailability for drug substances with long elimination half-lives (with PC-programs for the method of truncated areas). Computer Meth Programs Biomed 1992:39:61-73.
5. Albert KS, Smith RB: Bioavailability assessment as influenced by variation in drug absorption. In: Albert KS (ed.) Drug absorption and disposition: statistical considerations. American Pharmaceutical Association, Washington, DC., 1980:87-113.
6. Urso R, Aarons L: Bioavailability of drugs with long elimination half-lives. EurJ Clin Pharmacol 1983:25:689-693.
7. Schuirmann DJ: A comparison of the two one-sided procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987:15:657-680.
8. Shah VP, Yacobi A, Barr \VH, Benet LZ, Breimer D, Dobrinska MR, et al: Evaluation of orally administered highly variable drugs and drug formulations. Pharm Res 1996:13:1590-1594.
9. Fahr A: Cyclosporin clinical pharmacokinetics. din Pharmacokinet 1993:24:472-495.
10. Kovarik JM, Mueller EA, Kallay Z, Smith HT, Lison AE, Arns W, Renner E: Concentration-guided strategies in drug development: experience with a cyclosporine analog in transplantation. J Clin Pharmacol 1995;35:1136-1143.
11. Kovarik JM, Mueller EA, Niese D: Clinical development of a cyclosporine microemulsion in transplantation. Ther Drug Monit 1996:18:429-434.
12. Lush RM, Meadows B, Fojo AT, Kalafsky G, Smith HT, Bates S, Figg WD: Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist. J Clin Pharmacol 1997;37:123128.
13. McGilervay IJ, Midha KK, Skelly JP, Dighe S, Doluisio JT, French IW, et al: Consensus report from "Bio International "89": issues in the evaluation of bioavailability data. J Pharm Sci 1990; 79:945-946.